Search Results

FDA Approves Lantheus' Bravnetsa for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) has formally approved Lantheus Holdings' radioligand therapy drug Bravnetsa (lutetium Lu 177 dotatate injection) for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approved indication covers neuroendocrine tumors originating from the foregut, midgut, and hindgut. Following FDA review, Bravnetsa has been determined to be bioequivalent and therapeutically equivalent to Novartis'...

2026-09-27

Nuclea to Explore Building Nuclear Test Reactor in Utah to Advance Morpheus Microreactor Deployment

On August 5, Mangoceuticals announced that Nuclea Energy USA Inc., a wholly owned subsidiary of its merger partner, has signed a memorandum of understanding with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah St. Rafael Energy Laboratory to advance the deployment of the Morpheus microreactor. Under the MOU, Nuclea USA and the Utah Office of Energy Development will collaborate on test reactor siting and support related communications and coordination with the U.S. Department of Energy and the U.S. Nuclear Regulatory Commission. The parties will also evaluate pathways for future deployment of Nuclea's technology in Utah. The collaboration is seen as a step in Nuclea's micro modular react...

2026-08-06

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

Mangoceuticals to Merge with Nuclea to Advance Morpheus Microreactor to Market

Mangoceuticals announced on July 30 that it has signed a definitive business combination agreement with advanced nuclear technology company Nuclea Energy Inc., aiming to bring the latter's Morpheus microreactor to the public capital markets. Nuclea was founded in August 2023 and is headquartered in Mississauga, Ontario, Canada, focusing on the development of lead-cooled, factory-fabricated micro-modular reactors. Under the agreement, a newly formed subsidiary of Mangoceuticals will merge with Nuclea, and the combined company will operate as an indirect wholly owned subsidiary of Mangoceuticals. Upon completion of the transaction, holders of Nuclea common shares will receive...

2026-07-31

X-energy Joins Project Prometheus, Supporting AI-Driven Nuclear Energy R&D with Xe-100 and TRISO-X

On July 22, X-energy announced it had become a founding member of the "Prometheus" initiative and would participate as a Tier 1 partner. Led by Idaho National Laboratory (INL), NVIDIA, and Amazon Web Services (AWS), the initiative aims to levera

2026-07-23